- LOGIN
- MemberShip
- 2026-03-14 22:26:28
- Company
- Verzenio attempts reimb in early breast cancer in Korea
- by Eo, Yun-Ho Dec 20, 2022 06:06am
- The anticancer drug ‘Verzenio’ is attempting reimbursement listing for early breast cancer in Korea. According to industry sources, Lilly Korea has recently submitted an application for the reimbursement listing of its CDK4/6 inhibitor ‘Verzenio (abemaciclib)’ as a treatment for early-stage breast cancer with a high risk of recurrence. The company has been rapidly progressing its reimbursement procedure since the drug’s indication was expanded last month. The drug was approved by the Ministry of Food and Drug Safety as an adjuvant treatment for adult patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-), node-positive, early breast cancer (EBC) at high risk of recurrence, in combination with endocrine therapy. Verzenio’s efficacy in early breast cancer was demonstrated through the monarchE trial. The Phase III monarchE trial was the only trial to confirm successful results in 20 years as an adjuvant treatment for HR+/HER2- early breast cancer in combination with endocrine therapy in 20 years. The results from Cohort 1 of the monarchE trial, which became the basis for the indication expansion last month, showed that Verzenio+endocrine therapy not only demonstrated a reduction in the risk of recurrence compared to endocrine therapy alone through an improvement in invasive disease-free survival (IDFS), but it also confirmed a reduction in risk of remote recurrence through an improvement in distant relapse-free survival (DRFS). Joohyuk Sohn, Professor of Medical Oncology at Severance Hospital said, “Early breast cancer patients mainly experience recurrence after primary treatment in their first 1-2 years. This is why these patients need a more effective adjuvant treatment to reduce the risk of recurrence and death. An unmet medical continued to exist in the field due to a lack of new treatment options for patients with HR+/HER2- early breast cancer after the introduction of aromatase inhibitors in the early 2000s." Verzenio is currently reimbursed in Korea for the treatment of HR+, HER2- advanced or metastatic breast cancer ▴ in combination with an aromatase inhibitor for postmenopausal women as initial endocrine-based therapy; ▴in combination with Faslodex for women with disease progression following first-line therapy.
- Company
- MSD-Boryung Bio will copromote Prodiax 23 in Korea
- by Dec 20, 2022 06:05am
- On the 19th, MSD Korea announced it has selected Boryung Biopharma as its new distributor and supplier for its pneumococcal vaccine, ‘Prodiax 23.’ Under the agreement, Boryung Biopharma will be distributing and supplying both the private and contract Prodiax 23 products under the National Immunization Program starting January 1, 2023. MSD Korea’s copromotion agreement with its previous supplier, HK.Inno.N, is set to end at the end of this year. MSD Korea explained that the agreement had been made after reviewing the company’s vaccine product portfolio and long-term strategy from various angles. Boryung Biopharma’s main portfolio consists of vaccines and biological agents and owns a stable cold chain system. MSD Korea believed that Boruyng Biopharma’s experience in directly supplying flu vaccines for the NIP will create a synergy effect. MSD’s 23-valent pneumococcal polysaccharide vaccine, Prodiax23, was approved in 2000. The vaccine covers the widest spectrum of serotypes among pneumococcal vaccines available in Korea. People aged 65 or older may receive pneumococcal vaccines for free under the NIP. Jaeyong Cho, Executive Business Unit Director of Vaccines at MSD Korea, explained, “The interest and demand for our pneumococcal vaccine has been rising in line with the rising public interest in infectious respiratory diseases. Our agreement with Boryung Biopharma was made to instantly and actively respond to this rise in demand.”
- Company
- Shingrix presents a new paradigm for shingles prevention
- by Eo, Yun-Ho Dec 20, 2022 06:05am
- Professor YoonKorea GSK's herpes zoster vaccine "Shingrix" announced its official launch. GSK held a press conference at InterContinental Seoul COEX on the 15th to commemorate the launch of Shingrix, a shingles-prevention vaccine, in Korea. At the meeting, Yoon Kyung-young, an infectious medicine professor at Korea University Anam Hospital, introduced the epidemiology of shingles, the risk of diseases and complications, and strategies to prevent shingles through unmet needs and vaccines. Shingles occur when the varicella-zoster virus, a chickenpox-causing virus, is reactivated. Shingles are accompanied by unbearable pain, and some patients may experience neuralgia (post-shingles neuralgia) that lasts for months to years even after the shingles rash disappears. Professor Yoon said, "The risk of shingles is increasing in the elderly, where the immune system is strong and cannot maintain an effective immune response due to aging. "In the elderly and immunodeficiency cases, chronic pain caused by neuralgia after shingles, as well as complications such as invasion of eye nerves, facial paralysis, and damage to the auditory nerve are often leading," he explained. In addition, "Sherpas zoster complications lower the quality of life of patients, so it is important to prevent it in advance as a shingles vaccine." Shingrix emphasized that it will present a new paradigm for preventing herpes zoster in Korea as the first and only recombinant inactivation vaccine in Korea that has proven its preventive effect and safety profile through global clinical research. Under the theme of "Major Clinical Research Results of R&D and Shingrix in Recombinant Shingles Vaccine (RZV)," Kim Hyung-woo, managing director of GSK Medical Department, explained the implications of Shingrix's innovative mechanism and development. Shingrix, a Recombinant Zoster vaccine, is the first shingles vaccine in Korea approved by combining GSK's immune enhancer with a non-live antigen. It can help prevent the risk of developing shingles in adults over the age of 50 due to naturally weakened immunity due to aging. Shingrix showed 97.2% preventive effect in two global phases 3 clinical trials (ZOE-50, ZOE-70) conducted on 15,411 adults over the age of 50, and more than 90% preventive effect in all age groups over the age of 70. Significant adverse reactions were similar in the Shingrix administration group and the placebo administration group. An interim analysis of ZOSTER-049 (ZOE-LTFU) conducted by an extensive study of ZOE-50 and ZOE-70 confirmed that the shingles-prevention effect of Shingrix persists for at least 10 years after initial inoculation. In addition, Shingrix confirmed the safety profile through five clinical trials targeting immunocompromised people aged 18 or older. Based on this, Singrix can be vaccinated even in immunosuppressive diseases such as autologous hematopoietic stem cell transplant patients, solid cancer, blood cancer, and solid organ transplant patients, which have a higher risk of shingles than the general public. "Based on a number of clinical results, Shingrix is an innovative vaccine that is recommended to prevent shingles in adults over 50 years of age, not only in the United States but also in Canada, Germany, and the Netherlands, so it can be an effective alternative to prevent shingles in Korea," Kim said. Meanwhile, Shingrix was approved by the Ministry of Food and Drug Safety in September last year. It can be used for the purpose of preventing shingles in adults over 50 years of age or over 18 years of age who are at high or expected to have an increased risk of shingles due to immunodeficiency or immunosuppression due to disease or treatment. It is available in more than 20 countries worldwide, including the United States, Canada, Germany, Belgium, Australia, and Japan. In Korea, vaccinations are expected to be available at major general hospitals, hospitals, and clinics across the country starting this week.
- Company
- Reimb for Revlimid as maintenance therapy near after 4 yrs
- by Eo, Yun-Ho Dec 19, 2022 04:35am
- After 4 long years of await, Revlimid as maintenance therapy is nearing reimbursement listing in Korea. According to industry sources, the agenda of reimbursing Revlimid as maintenance therapy that has passed deliberations by the Health Insurance Review and Assessment Service’s Cancer Disease Deliberation Committee in June will be deliberated at this year’s final Health Insurance Policy Deliberation Committee meeting. If this last procedure progresses and is completed without issues, the drug’s reimbursement is expected to be expanded from 2023. The agenda of using Revlimid as maintenance therapy had undergone various twists and turns in Korea. Since 2019, BMS Korea had actively sought to list the drug for reimbursement, but made no progress. The agenda has also been listed for deliberation by the CDDC in September 2019, June 2020, then again in September last year at the CDDC meeting that gained attention due to its deliberation of the CAR-T therapy ‘Kymriah (tisagenlecleucel),’ but to no avail. “A drug that prevents or delays recurrence of cancer” This is an extraordinary concept. All cancer survivors would jump to take that option. Revlimid has presented such an option for the first time in the field of multiple myeloma, a type of blood cancer that has a recurrence rate of 70-80%. The National Comprehensive Cancer Network made a Category 1 recommendation for the Revlimid maintenance therapy as the only option allowed for in all patients, regardless of eligibility for transplant. The European Society for Medical Oncology guidelines also recommends Revlimid as the only maintenance therapy to be used after autologous stem-cell transplantation. The significance of Revlimid, which has settled as the global standard of care as a maintenance therapy, has been demonstrated through a meta-analysis of 3 clinical trials (CALGB 100104, IFM 2005-02, GIMEMA RV-MM-PI-209). In a median follow-up of 79.5 months on 1,209 patients, PFS (progression-free survival) of patients that used Revlimid maintenance as monotherapy was 52.8 months, which was a significant improvement from the 23.5 months observed in the control arm that did not use maintenance therapy. the study demonstrated Revlimid’s clinical efficacy with more than double extension in PFS. In the follow-up study that was conducted for 88.8 months, the OS (overall survival) of the control group that did not receive maintenance therapy was 86.9 months. On the other hand, the Revlimid maintenance therapy arm’s OS was 111 months, demonstrating a significant improvement. The study showed that maintenance therapy can be a solution to prevent recurrence and improve the quality of life in multiple myeloma patients that experience frequent recurrence. Since patients with multiple myeloma experience worse symptoms when their cancer recurs, it is most important to prevent or delay recurrence after transplantation. Ki-Hyun Kim, Professor of Hemato-oncology at the Samsung Medical Center (Chair of the Multiple Myeloma Research Committee of the Korean Society of Hematology), said, “The prognosis for multiple myeloma deteriorates significantly and the treatment options narrow greatly with every recurrence, therefore using good treatments at the start of treatment is important. It is a shame that we cannot actively recommend maintenance therapy to patients despite their proven clinical efficacy due to the realistic issue of ‘non-reimbursement’.” “If the maintenance therapy is also approved for reimbursement in addition to RVD therapy, it will greatly improve the long-term quality of life in patients in Korea.”
- Company
- Severe asthma treatment Fasenra seeks reimb in KOR
- by Eo, Yun-Ho Dec 19, 2022 04:34am
- Another severe asthma treatment is attempting insurance reimbursement in Korea. According to industry sources, AstraZeneca is undergoing the reimbursement process for its monoclonal antibody for asthma, Fasenra (benralizumab). Other biological drugs including GSK’s ‘Nucala (mepolizumab),’ and Teva-Handok’s ‘Cinqair (reslizumab)’ have also been reattempting reimbursement in Korea as well. Fasenra was approved in Korea in 2019 as an add-on maintenance treatment in adults with severe eosinophilic asthma inadequately controlled with existing treatment options. The drug is administered once every 4 weeks for the first 3 months, then every 8 weeks thereafter. One of the main purposes of asthma management is to reduce the risk of asthma exacerbations. Fasenra directly binds to the alpha subunit of the interleukin-5 receptor (IL-5Rα) to induce apoptosis. The drug demonstrated efficacy in reducing asthma exacerbation and improving lung function. In the global SIROCCO trial that was conducted to evaluate the effect of Fasenra in treating asthma exacerbations in 1,205 asthma patients including 122 Korean patients, the annual rate of clinically significant asthma exacerbations was reduced by 45% in patients who were treated with Fasenra once every 4 weeks, and by 51% in patients who were treated with Fasenra once every 8 weeks. Also, in the CALIMA trial, Fasenra demonstrated a significant reduction in asthma exacerbations compared to the placebo. In the trial, the annual rate of asthma exacerbations was reduced by 36% in patients who were treated with Fasenra once every 4 weeks, and by 28% in patients who were treated with Fasenra once every 8 weeks compared with placebo. In both trials, a change from baseline in mean FEV1 (forced expiratory volume in 1 second) was observed using Fasenra, and a consistent improvement compared with placebo. The long-term efficacy and safety of Fasenra in severe eosinophilic asthma were evaluated through the BORA trial, a long-term extension trial on 1,926 patients that participated in the SIROCCO and CALIMA trials. In terms of safety, Fasenra showed no significant difference compared to the placebo, and 72% of the patients that were administered Fasenra did not experience asthma exacerbations and were able to maintain their FEV1. Surprisingly enough, asthma is associated with a high mortality rate. The mortality rate of hospitalized patients due to asthma exacerbation is nearly 1/3, and the expenses spent by patients that require emergency treatment or hospitalization due to asthma exacerbation account for more than 80% of the total asthma-related cost, representing a high burden of social cost. Eosinophilic inflammations are found in 50% of all asthma patients and may lead to reduced lung function or asthma exacerbations. In particular, eosinophilic asthma patients that show increased blood eosinophil levels despite appropriate ICS therapy are inadequately controlled with existing treatment therapy including ICS and LABA therapy. Therefore, the quality of life of these patients is threatened by the pain caused by the symptoms and the frequent exacerbation of the disease. Meanwhile, AstraZeneca sought to expand its indication to uncontrolled Fasenra to chronic rhinosinusitis with nasal polyp (CRSwNP), but FDA turned down the final approval and requested additional data.
- Company
- Asthma treatment Cinqair attempts reimb again in Korea
- by Eo, Yun-Ho Dec 15, 2022 05:55am
- The asthma treatment Cinqair for asthma is again attempting reimbursement listing in Korea. According to industry sources, Teva-Handok has recently submitted an application for the reimbursement listing of its interleukin-5 antagonist monoclonal antibody Cinqair (reslizumab). Following Cinqair’s steps, other biological drugs for asthma including GSK Korea’s ‘Nucala (mepolizumab) are also moving to start their reimbursement listing processes as well. As an interleukin-5 antagonist, Cinqair reduces levels of blood eosinophils, a type of white blood cell that is involved in the development of asthma exacerbation. The drug had first been first approved in Korea in 2017 as an add-on maintenance treatment for adult patients with an eosinophilic phenotype of asthma (those who have a blood eosinophil count of at least 400/㎕ before treatment) that were not adequately controlled with existing treatments. The company had applied for its reimbursement being launched without reimbursement in 2018 but failed. Teva-Handok has been jointly marketing Cinqair with Handok Pharmaceutical since its release. Meanwhile, Cinqair’s efficacy had been demonstrated through five placebo-controlled clinical studies that evaluated the safety and efficacy of Cinqair 3mg/kg in 1,028 adult and adolescent asthma patients that were uncontrolled with currently available therapies. In three Phase III clinical trial programs that were conducted on asthma patients with high blood eosinophil counts, Cinqair reduced the frequency of asthma exacerbations by up to 59% and significantly improved lung function, symptoms, and the asthma-related quality of life. Also, Cinqair received attention for releasing the post-hoc analysis results of asthma patients that require Step 4 and Step 5 treatment among all patients that participated in the Phase III trials. Cinqair reduced the clinical degree of asthma exacerbations in patients classified as Step 4 or 5 under the Global Initiative for Asthma guidelines by 53% and 72%, respectively, and increased the level FEV1 (forced expiratory volume in 1 second) by 103ml in Step 4 patients and by 237ml in Step 5 patients, demonstrating that the benefit was found to be greater in Step 5 patients.
- Company
- Verzenio expects to address the unmet demand
- by Eo, Yun-Ho Dec 15, 2022 05:55am
- Professor Son Joo-hyuk Expectations are high for securing early breast cancer indications for Verzenio, a breast cancer treatment with CDK4/600 inhibition mechanism. Lilly Korea held a press conference on the 14th to commemorate the expansion of permission for early breast cancer indications at high risk of recurrence of the anticancer drug Verzenio. Verzenio obtained approval from the Ministry of Food and Drug Safety on the 18th of last month as a treatment used in combination with hormone receptor-positive, human epithelial cell growth factor 2 negative (HR+/HER2-), early breast cancer adult patients at high risk of recurrence of lymph node-positive, and endocrine therapy. Verzenio's approval is meaningful in that the first CDK 4&6 inhibitor for early breast cancer patients at high risk of HR+/HER2-lymph node-positive recurrence was introduced in Korea. Sohn Joo-hyuk, a professor of oncology at Severance Hospital, shared the medical unfulfilled needs of HR+/HER2-lymph node-positive recurrence early breast cancer patients and the clinical value of Verzenio confirmed through the monarch clinical study, which was the background of approval of MFDS. In the first topic of the presentation, "HR+/HER2-High-Risk Early Breast Cancer Patients' Medical Unfulfilled Demand," Professor Sohn said, "Most of the female cancers in Korea are diagnosed early due to screening activation, especially in the standard treatment of HR+/HER2- patients, to prevent recurrence after surgery. He added, "The prognosis of HR+/HER2-early breast cancer is generally known to be good, but high-risk patients are highly likely to recur, making it difficult to expect long-term survival." According to domestic statistics, the survival rate of general early breast cancer patients is more than 90%, which is higher than that of other diseases. However, patients with recurrence risk factors such as lymph node-positive, high tumor grade, large tumor size, and fast cell proliferation are known to have a higher risk of remote recurrence and death than general patients. Studies have shown that if the tumor size exceeds 5cm, the 5-year survival rate of breast cancer patients decreases from 57% (without lymph node metastasis) to 21% (with lymph node metastasis). Professor Son said, "The recurrence of early breast cancer patients after the first treatment is usually one to two years, and more effective postoperative auxiliary treatment is needed to reduce the risk of recurrence and death." However, since the introduction of aromatase inhibitors in the early 2000s, the absence of new treatment options for HR+/HER2-early breast cancer patients has led to a medical non-fulfillment demand." Verzenio's monarch clinical trial is the only study that has confirmed successful results in about 20 years as a combination of endocrine therapy as an adjunct treatment for HR+/HER2-early breast cancer. In monarch cohort 1, which served as the basis for this indication expansion permit, Verzenio+ endocrine therapy confirmed remote recurrence risk reduction results through Distance Relapse-Free Survival (DRF) indicators as well as Invisible Disease-Free Survival (IDFS) indicators compared to endocrine therapy alone.
- Company
- Samsung Epis's Soliris biosimilar bioequivalent to original
- by Dec 14, 2022 05:56am
- Study results that show Samsung Bioepis’s Soliris biosimilar is bioequivalent to the original drug have been presented. On the 13th, the company announced that its biosimilar, SB12 has demonstrated equal effect to its original drug Soliris at the American Society of Hematology (ASH) Annual Meeting that is being held in New Orleans. Soliris is a rare disease treatment used to treat incurable rare diseases like paroxysmal nocturnal hemoglobinuria (PNH) that was developed by the US pharmaceutical company Alexion. SB12 is a biopharmaceutical drug developed using the same active ingredient contained in Soliris, eculizumab. Samsung Bioepis presented statistical analysis results in the form of a poster to add credibility to the clinical results through additional analysis of its Phase III clinical trial. The company had previously demonstrated the bioequivalence of SB12 to Soliris in terms of clinical efficacy and safety through a Phase III trial that had been conducted from 2019 to last year. The primary efficacy endpoint of the SB12 Phase III trial was the level of lactate dehydrogenase (LDH) at Week 26 and the time-adjusted area of under the effect curve (AUEC) of LDH from Week 14 to Week 26 and from Week 40 to Week 52. The red blood cell of patients are destroyed and LDH is released into the blood when a patient develops PNH. LDH is one of the biomarkers that can diagnose this. Elevated LDH levels are usually associated with liver disease and increased fatigue, etc. The trial looked at the time-adjusted area under the effect curve (AUEC) of LDH from Week 14 to Week 26 and from Week 40 to Week 52 to observe whether these levels were similar to the original. Results showed that the LDH level lay within the pre-defined equivalence margin, indicating that the SB12 was bioequivalent to the original drug. Samsung Bioepis conducted a further sensitivity analysis to add reliability to the accuracy of the results of the Phase III trial. Statistical analysis derived the same conclusions as the primary efficacy endpoint results that were observed in the Phase III trial. An official from Samsung Bioepis said, “SB12 contains the core purpose of biosimilars that seek to expand patient access to expensive medicines. We will continue to make efforts to provide more treatment opportunities to patients suffering from rare diseases.”
- Company
- Champix supply interruption
- by Kim, Jin-Gu Dec 14, 2022 05:56am
- Jeil Pharmaceutical's Nico Chams has dominated the market for anti-smoking treatment aids with Varenicline ingredients. Analysts say that while sales of major products, including Pfizer Champix, were suspended due to the detection of impurities in NNV components in September last year, it succeeded in digging into the gap and raising its influence to the level of market monopoly. ◆ First Pharmaceutical's Nico Chams share is 1% to 87% According to IQVIA, a pharmaceutical market research firm on the 13th, Jeil Pharmaceutical's Nico Chams' cumulative sales in the third quarter were 7.3 billion won. It increased more than nine times from 800 million won accumulated in the third quarter of last year. Sales have risen vertically since a series of impurities were detected in the anti-smoking treatment aid containing Varenicline in September last year. At that time, the Ministry of Food and Drug Safety announced the results of the NNV detection test on Varenicline-based drugs and decided to suspend sales only for products exceeding 185 ng/day. Products with a detection amount of 733 ng/day or more were ordered to be recovered. Among the products that were distributed in Korea, sales of seven products that CTC Bio had commissioned and one product that Pfizer Pharmaceutical Korea imported have been suspended. Nineteen manufacturing number items from three companies produced by CTC Bio have been ordered to be recovered. Pfizer Pharmaceutical Korea voluntarily recalled it. In the case of products produced by Jeil, impurities were detected for 16.70 to 43.28 ng/day, and they survived the recovery as well as the suspension of sales. Nico Chams' share also increased significantly around this point Until the second quarter of 2021, just before the suspension of sales, Nico Chams' market share was only 0.7%. However, the market share jumped to 24% in the third quarter of 2021, right after the suspension of sales. It then increased to 68% in the fourth quarter, and further expanded to 87% in the third quarter of this year. Based on sales in the third quarter, Nico Chams is actually over-exclusive with 2.4 billion won, and the rest is less than 200 million won. ◆Varenicline Market 34% in a Year↓ The lack of smoking cessation business overlaps with the prolonged suspension of sales. With the withdrawal of major products, the size of the anti-smoking treatment aid market for Varenicline ingredients decreased by 34% from 13 billion won in the third quarter of last year to 8.6 billion won in a year. This market has been on the decline for the past four consecutive years. As the government launched an anti-smoking treatment support project in 2015, the market expanded to 65 billion won in 2017 but has since shrunk to 16.2 billion won last year as it has steadily declined. This is the result of a combination of a reduction in drug prices and a decrease in the number of participants in the anti-smoking treatment project. On top of that, it is expected to decrease further this year due to the prolonged suspension of sales of impurity drugs that occurred in the third quarter of last year. Champix, which previously led the market, has still been suspended from sales and distribution as the impurity issue has not been resolved. Champix's sales plunged from 4.6 billion won in the second quarter of last year to 600 million won in the third quarter. Since then, sales of less than 10 million won have been recorded every quarter. Pfizer Pharmaceutical Korea said, "We are waiting for the resumption of supply at the global headquarters," adding, "We do not know the plans for the resumption of sales at this time."
- Company
- 2022 Pharmaceutical Industry Advertising Target Call Members
- by Dec 14, 2022 05:56am
- Dailypharm held the 2022 Pharmaceutical Bio Industry Advertising PR Awards on the 7th. Representative Lee Jung-seok (6th from left) and the winnersDaewon Pharmaceutical's "Coldewon" and Sanofi's "Honey Jam Market for Those Who Can't Sleep" won the grand prize in the advertising and PR categories at the 2022 Korea Pharmaceutical Bio-Industry Advertising and PR Awards. Chong Kun Dang Benfobell won the grand prize in the "Special Award for Pharmacist Selection" category, which was decided by the votes of pharmacists. Dailypharm (CEO Lee Jung-seok) held an award ceremony for the 2022 Korea Pharmaceutical Bio-Industry Advertising and PR Awards at the Diamond Hall of InterContinental Seoul COEX Hotel on the 7th. More than 200 advertising and public relations officials from domestic and foreign pharmaceutical bio companies, including Won Hee-mok and Lee Young-shin, vice chairman of KRPIA, attended the event. At the ceremony, which marks its 10th anniversary this year, a total of 72 works were submitted in five categories, including TV, printing and radio, the Internet, and PR. More than 200 advertising and PR workers from the pharmaceutical bio-industry attended the event The awards were divided into advertising and PR categories. The advertising sector was divided into two categories: TV, Internet, and radio. The grand prize in each field and three excellence awards were selected along with the grand prize. In the PR category, the grand prize, one grand prize, and three excellence awards were honored. A special award was also given to 1,300 pharmacists who voted directly. Daewon Pharmaceutical's Coldewon won the grand prize in this year's advertising category. The award-winning work was awarded a prize of 5 million won along with the trophy. Yoo Seong-kwon, director of Daewon Pharmaceutical, said, "This year seems to have been a year when Coldewon received a lot of attention and took a leap forward. I am grateful that I received that energy and received a good award, he said. "I will try to stand here next year with good advertisements for new items." In the TV category, Shinshin Pharmaceutical's Arex was selected as the best prize, and a prize of 3 million won was given along with the trophy. ▲ Sanofi Allegra, ▲ Ildong Pharmaceutical's Aronamin C Plus Tab, and ▲ Limited's Mag-B Speed Excellence Award. The excellence award was awarded a trophy and a prize of 2 million won. In the Internet/radio category, HKinno.N's "Condition" won the grand prize. ▲Houns Radio Corporate Advertising ▲ Johnson & Johnson Nicorette ▲ JW Pharmaceutical 'Himom bands' were selected for the Excellence Awards. The award-winning film was given a trophy and prize money. In the PR sector, there were many entries that threw meaningful messages, including social contribution activities. This year's PR category was won by Sanofi's campaign to improve awareness of atopic dermatitis diseases, Honey Jam Market for those who can't sleep. The award-winning work was awarded a prize of 5 million won along with the trophy. Kim Hyun-jung, director of Sanofi Specialty Care, said, "We have been campaigning to improve awareness of atopic dermatitis diseases for four years since 2019. This year, the "Honey Jam Market for People Who Can't Sleep" was held to form a consensus on the physical and mental pain of patients. It is an honor that the patient's sincerity has paid off with a good award. "I will continue to make efforts to hold various campaigns for patients," he said. Yoo Seong-kwon, director of Daewon Pharmaceutical (left), and Lee Jung-seok, CEO of Daily Farm, who won the Grand Prize in advertising Dongkuk Pharmaceutical's "pupil earthquake" campaign was selected as the best prize in the PR category. ▲Ginexin, the god of memory (SK Chemical) ▲Growup Bio-Up Campaign (Amgen Korea) ▲YYPharm, including blood donation of love, won the Excellence Award. In the special prize category selected by online voting of 1,300 pharmacists, Chong Kun Dang was selected as the Benfobell target and won a trophy and 5 million won in prize money. Lee Sang-soo, deputy director of Chong Kun Dang, said, "Since the launch of Benfobell, it has been loved by pharmacists so far. It has a special meaning because pharmacists voted for it themselves. I think it's thanks to your consistent communication with us. "I'll be Benfobell who works harder." Donghwa Pharmaceutical Itchi won the grand prize in the special award for pharmacist selection. ▲Master Pharmaceutical Mayqueen ▲ Dong-A Pharmaceutical Panpyrin and others received the Excellence Award. Ahn Dae-cheon, former chairman of the Korea Advertising Association (Professor of Inha University), was the judge, while Chung Jae-hoon, a professor at Chonbuk National University, and Lee Jae-guk, executive director of the Korea Pharmaceutical Bio Association, participated as professional judges. Ahn, chairman of the judging committee, said, "The review of the advertising sector was based on whether the message was well matched and clearly delivered, secondly on the novelty of the idea, and thirdly on the reliability of the information. The PR division considered whether it could contribute to enhancing its image from a long-term perspective and whether messages and activities could elicit timely and consumer sympathy, he said. "We praise your efforts to develop advertising and promotion in the pharmaceutical bio industry." The Korea Pharmaceutical Bio-Industry Advertising and PR Awards began in 2013 with the aim of encouraging advertising promoters who give new values to the pharmaceutical industry and drugs and encouraging pharmacists, who are primarily advertising consumers, to produce advertisements that form a consensus. Lee Jung-seok, CEO of dailypharm, said in a greeting, "Many excellent works have been submitted this year, so I would like to thank pharmaceutical bio officials. I would like to congratulate you on your award-winning work. "We will make it a more fruitful and beneficial event next year," he said. Sanofi Specialty Care Director Kim Hyun-jung and CEO Lee Jung-seok, who won the PR category grand prize Chairman Won Hee-mok then said, "In the age of aging, the category of health management and prevention along with treatment has expanded, and the proportion of OTC drugs is increasing. At the same time, as the subject of the information is digitally transferred to consumers, changes are taking place in general drug advertisements, he said. "I hope it will be a place to find a new paradigm of general drug advertisements." "Thank you to Daily Farm for planning the advertising and PR targets," he said. Vice Chairman Lee Young-shin said, "With the development of artificial intelligence and digital healthcare, it has become an era of understanding the development of science and technology in the global beyond Korea. Advertising and promotion of drugs is no exception, he said. "I would like to thank advertising and public relations officials and media officials who have recognized new changes and delivered more accurate information in the regulated healthcare industry and contributed to improving the quality of life of the people." "KRPIA will also make efforts to grow with the domestic pharmaceutical bio industry."
